# Beta-Blocker Evaluation in Survival Trial (BEST)

> **NCT00000560** · PHASE3 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)**

## Conditions studied

- Cardiovascular Diseases
- Heart Diseases
- Heart Failure, Congestive
- Heart Failure

## Interventions

- **DRUG:** adrenergic beta antagonists

## Key facts

- **NCT ID:** NCT00000560
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-06
- **Primary completion:** —
- **Final completion:** 1999-09
- **Target enrollment:** — (—)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000560, "Beta-Blocker Evaluation in Survival Trial (BEST)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00000560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*